BVS Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of 10.97% compared to Bioventus, Inc.'s net margin of -13.47%. Bioventus, Inc.'s return on equity of 13.53% beat Accuray, Inc.'s return on equity of -60.6%.

Bioventus, Inc. has a consensus price target of $14.80, signalling upside risk potential of 64.99%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 507.99%. Given that Accuray, Inc. has higher upside potential than Bioventus, Inc., analysts believe Accuray, Inc. is more attractive than Bioventus, Inc..

Bioventus, Inc. has a beta of 0.696, which suggesting that the stock is 30.382% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.317, suggesting its more volatile than the S&P 500 by 31.653%.

Bioventus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Bioventus, Inc. quarterly revenues are $157.9M, which are larger than Accuray, Inc. quarterly revenues of $102.2M. Bioventus, Inc.'s net income of $17.3M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Bioventus, Inc.'s price-to-earnings ratio is 26.80x while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus, Inc. is 1.05x versus 0.11x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of 10.97% compared to Bioventus, Inc.'s net margin of -10.21%. Bioventus, Inc.'s return on equity of 13.53% beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.

Bioventus, Inc. has a consensus price target of $14.80, signalling upside risk potential of 64.99%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.42 which suggests that it could grow by 125.45%. Given that Alphatec Holdings, Inc. has higher upside potential than Bioventus, Inc., analysts believe Alphatec Holdings, Inc. is more attractive than Bioventus, Inc..

Bioventus, Inc. has a beta of 0.696, which suggesting that the stock is 30.382% less volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.117, suggesting its more volatile than the S&P 500 by 11.658%.

Bioventus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

Bioventus, Inc. quarterly revenues are $157.9M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. Bioventus, Inc.'s net income of $17.3M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, Bioventus, Inc.'s price-to-earnings ratio is 26.80x while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus, Inc. is 1.05x versus 2.05x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 10.97% compared to Bioventus, Inc.'s net margin of 12.68%. Bioventus, Inc.'s return on equity of 13.53% beat Boston Scientific Corp.'s return on equity of 12.55%.

Bioventus, Inc. has a consensus price target of $14.80, signalling upside risk potential of 64.99%. On the other hand Boston Scientific Corp. has an analysts' consensus of $100.81 which suggests that it could grow by 60.48%. Given that Bioventus, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Bioventus, Inc. is more attractive than Boston Scientific Corp..

Bioventus, Inc. has a beta of 0.696, which suggesting that the stock is 30.382% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.926%.

Bioventus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Bioventus, Inc. quarterly revenues are $157.9M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Bioventus, Inc.'s net income of $17.3M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Bioventus, Inc.'s price-to-earnings ratio is 26.80x while Boston Scientific Corp.'s PE ratio is 32.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus, Inc. is 1.05x versus 4.74x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of 10.97% compared to Bioventus, Inc.'s net margin of -417.92%. Bioventus, Inc.'s return on equity of 13.53% beat Plus Therapeutics, Inc.'s return on equity of --.

Bioventus, Inc. has a consensus price target of $14.80, signalling upside risk potential of 64.99%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than Bioventus, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Bioventus, Inc..

Bioventus, Inc. has a beta of 0.696, which suggesting that the stock is 30.382% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

Bioventus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Bioventus, Inc. quarterly revenues are $157.9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Bioventus, Inc.'s net income of $17.3M is higher than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Bioventus, Inc.'s price-to-earnings ratio is 26.80x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus, Inc. is 1.05x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.